Thanks to a detailed global market research, Fosjoas products have avoided the defects of similar products and taken a leading position on certain fields, e.g., the ranger per charge is 1.5 times farther than that of other brands. Fosjoas is focusing on the development of lighter, smaller and fresher products to realize customers’ anticipation and optimize user’s experience. Let us find out the product idea behind Fosjoas newest product-K5 electric standing scooter.

Fosjoas products have avoided the defects of similar products and taken a leading position on certain fields, e.g., the ranger per charge is 1.5 times farther than that of other brands and a latest gear motor is engineered to power the unit. Fosjoas is focusing on the development of lighter, smaller and fresher products to realize customers’ anticipation and optimize user’s experience. The core idea is also shown on Fosjoas newest product-K5 electric standing scooter. Fosjoas products are currently applied to various sections.

For the design of Fosjoas K5 2-wheeled electric scooter, Fosjoas team has made a great deal of market investigation. For those who are in business travel, they will squeeze some time to walk around when they come to a new city, as it can release the heavy and busy work pressure. While, Taxi is unnecessary, as they usually will not go that far. You know, there will always be some emergency in the work. They need means of transport that are more convenient to carry around. This problem is not limited to the office workers, but also those who like to have a short distance travel on weekend. Here comes Fosjoas K5 electric scooter.

 Image: http://www.fosjoas.com/images/UpliadImg/Fosjoas_20160330095823940.jpg

Usually, in order to make an item more easily portable, the most appropriate approach is the adoption of folding structure. After countless hours of drawing and tests, Fosjoas team has finally found the ideal folding frame of Fosjoas K5 eco-friendly electric scooter. K5’s battery is built-out. It only takes a few seconds to disassemble and replace battery without any tools. In this way, K5 will meet different needs. Coupled with adjustable operating rod, Fosjoas K5 electric scooter for adults is suitable for riders with different heights.

Taking the riders’ actual needs into consideration is the product idea behind Fosjoas K5.

Media Contact
Company Name: Moben Intl(england) Co., Limited
Contact Person: Jason
Email: moben@fosjoas.com
Phone: +86-75583777600
Country: United Kingdom
Website: http://www.fosjoas.com/

Source: ABNewswire

ReleaseID: 57836

March 31, 2016 – – TheProductLawyers.com discusses reported clinical trial indications of increased heart attack risks within the initial 30 days of treatment among patients using Invokana. Invokana is a new-generation, type-2 diabetes drug manufactured by Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation). The noted risks were highlighted during the drug’s clinical trials, apparently connecting the use of the drug to possible heart issues.

In March of 2013, Invokana was the first of a group of similar SGLT2 class inhibitor drugs to be approved by the U.S. Food and Drug Administration (FDA) and released to market for public use. It was reported, however, that during clinical trials conducted on the drug, 13 patients using it suffered from major cardiovascular events (such as heart attacks or strokes) within their initial 30 days of treatment. Results also showed that after this 30-day time period, the risk for these events to occur suddenly equalized.

The New York Times addressed these findings and the apparent lack of a warning that they may occur on the drug’s label, noting, “The label of the drug includes no warnings about heart attacks or strokes. …The FDA is requiring Johnson & Johnson to conduct five post-marketing studies, including a clinical trial to determine more definitively if the drug increases those risks.”

Heart attacks are caused when something inside a patient’s body stops blood flow to their heart. This blockage is typically caused by blood clots. Because it stops the heart from obtaining enough oxygen, the muscle of the heart starts to die. If severe tissue damage is sustained during this time, the heart will be unable to pump blood through the body, and the heart attack could become fatal.

The attorneys of Banville Law understand how concerning this potential side effect link is for patients currently using Invokana, especially those within their first 30 days on the medication. They are dedicated to keeping the public informed regarding Invokana information or important information on other drugs. To accomplish this, they sponsor the website TheProductLawyers.com. At this time, the attorneys of Banville Law are also working to help those who have taken Invokana or similar SGLT2 class inhibitor drugs and who have experienced health problems that they believe were caused by the drugs. They hope to help ensure that affected individuals are given the opportunity to investigate their legal rights in the matter. These individuals may be entitled to significant compensation through legal action. To help those wishing to discuss this possibility, the attorneys of Banville Law are offering complimentary Invokana consultations at this time.

To ask questions or request additional information on Invokana lawsuits, please contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009004

March 31, 2016 – – BloodThinnerHelp.com reports on the rather consistent surge of filings from Xarelto lawsuit plaintiffs. These complaints have been filed against defendants Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation), who manufacture the new-generation blood thinner. Lawsuit plaintiffs now number more than 3,400 in the United States, and are separated into two main groupings. Federally-filed Xarelto lawsuits were transferred and consolidated to form MDL number 2592 in the Eastern District of Louisiana. These cases are being overseen by the Honorable Judge Eldon Fallon and number over 2,800 at this time. In addition, there are more than 600 Xarelto lawsuits which have been consolidated to form a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.

Thousands of lawsuit plaintiffs involved share strikingly similar allegations against Xarelto manufacturers. These allegations name a range of dangerous bleeding events, some of which were fatal, and all of which the plaintiffs claim were caused by the anticoagulant drug. In addition, plaintiffs allege that the defendants were negligent by not properly warning consumers and medical professionals about the dangerous risks associated with the use of their product.

Those who are awaiting what they call justice have found comfort through the results of very similar previously settled lawsuits regarding blood thinner Pradaxa. These complaints also increased rapidly in number and grew to include thousands of lawsuits. Pradaxa cases resulted in a settlement by the defendant outside of court, and many Xarelto lawsuit plaintiffs are hoping for a similar outcome.

Those closely involved believe that lawsuit numbers will continue to grow over time. The plaintiffs are awaiting bellwether trials which are currently scheduled to be heard in early 2017. As they await these trials, Attorney Joseph Osborne is working to help others who have used Xarelto and who believe that they were negatively affected by the drug. He wishes to help ensure that these individuals will be provided with the important opportunity to explore their legal options in the matter. Those affected could be entitled to significant compensation gained through legal action. In order to better assist those interested in legal action, Attorney Osborne is currently offering free legal consultations for affected parties.

To request additional Xarelto lawsuit information, or to ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009005

March 31, 2016 – – BloodThinnerHelp.com reports on the new study published in HealthyDay News suggesting Warfarin may raise the risk of severe bleeding inside the skull. Nearly 32,000 U.S. veterans, age 75 and over, with atrial fibrillation were observed in the study by researchers. Those researchers found that one out of three of those subjects suffered an intracranial bleed while taking the blood thinning drug Warfarin for their heart condition.

The study’s results emerge amid thousands of pending cases against another blood thinning drug, Xarelto, which is manufactured by Johnson & Johnson and Bayer. Xarelto was compared to Warfarin in a double-blind trial and found to be the more effective of the two drugs. However, a recent New York Times article stated that the FDA is now investigating whether faulty equipment compromised the outcome. Since the clinical trial, thousands of lawsuits have emerged against the manufacturers of Xarelto claiming the patients that used the drug suffered adverse side effects including gastrointestinal bleeding, brain hemorrhages, internal bleeding, rectal bleeding, pulmonary embolisms, epidural hematoma, stroke and heart attacks.

Federal cases filed against the manufacturers of Xarelto have been combined into a multidistrict litigation panel in New Orleans, Louisiana. Those filed in the commonwealth of Pennsylvania have been assigned to a mass tort program for more efficient managing. Federal cases have since reached almost 3,000 in number and those filed in Pennsylvania have reached 620 cases.

The first lawsuit filed against Xarelto claiming the drug was the reason for a patient’s death was filed in January 2014. At that time there was no corresponding antidote for the drug which means that extreme measures had to be taken in emergency bleeding situations. .

For those still waiting for their day in court, Attorney Joseph Osborne is working to help ensure that anyone who has taken Xarelto and believes they have experienced negative side effects as a result of the drug will be given the chance to investigate their legal rights. Qualifying individuals could be entitled to legal action and significant compensation. Attorney Osborne is offering complimentary legal consultations to affected parties at this time.

To request further Xarelto information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008999

The global market for glucose monitoring devices is projected to reach $ 14 billion From 2006 To 202.

The glucose monitoring devices market is one of the fastest-growing markets. The global market for glucose monitoring devices is projected to reach $ 14 billion over the forecast period, growing at a healthy compound annual growth rate (CAGR) of 6 percent. The key aspects driving the global glucose monitoring devices market include the increasing occurrences of diabetes across the globe, progressively improving understanding about the advantages of regular glucose monitoring and the availability of highly developed solutions for regular glucose monitoring, based on various technologies like Continuous Glucose Monitoring (CGM), that boost the effectiveness of the glucose monitoring testing procedures. However, due to the lack of knowledge about using highly developed glucose monitoring technologies, as well as the higher costs, the global glucose monitoring devices market could face a challenge. The market is further categorized by applications and regions.

Browse Full Research Report With TOC on http://www.radiantinsights.com/research/market-snapshot-glucose-monitoring-devices-2006-to-2020-southeast-asia-taiwan-indonesia-malaysia-singapore-vietnam

Based on the end-use industries, the global market for glucose monitoring devices is divided into three application segments namely private clinics, hospitals, and self-based glucose testing. The hospitals segment accounted for the maximum market share in 2014 and it is expected that the self-based glucose testing segment will acquire the maximum market share in the near future eventually generating maximum revenue. On the basis of analysis, the global glucose monitoring devices market is divided into quantitative & qualitative tests. One of the most regular qualitative tests used for testing blood glucose levels is the Benedict test. Some other such quantitative & qualitative tests include Osazone test, Barfoed’s test, and others.

Geographically, the global glucose monitoring devices market is divided into the Middle East & Africa, North America, Asia-Pacific, Europe, and Latin-America. North-America followed by Europe accounted for the highest market share in 2014. The regions of Asia-Pacific are likely to show a huge growth due to changing lifestyle patterns, high living standards, growing awareness among people, and the usage of pre-filled syringes among the population.

Browse All Reports of This Category at:  http://www.radiantinsights.com/catalog/medical-devices

The key players of the global glucose monitoring devices market are GlySens Inc., Nova Biomedical Corporation, Abbott Laboratories Inc., Dexcom Inc., Bayer AG, Senseonics, Eli Lilly and Company, Insulet Corporation, Medtronic, F. Hoffmann-La Roche Ltd., and LifeScan Inc.

Explore Other Reports By Radiant Insights, Inc at

• Gaskets & Seals Industry:
  http://www.radiantinsights.com/research/gaskets-amp-seals-industry-forecasts-china-focus

• Hepatitis Drugs Industry:
  http://www.radiantinsights.com/research/hepatitis-drugs-industry-forecasts-china-focus

• Advanced Materials Industry:
  http://www.radiantinsights.com/research/advanced-materials-industry-forecasts-china-focus

About Radiant Insight

Radiant Insights is a market research and consulting company offering syndicated research studies, customized reports, and consulting services. Our market research studies are designed to facilitate strategic decision making, on the basis of extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Using a patented and robust research methodology, we publish exhaustive research reports covering a host of industries such as Technology, Chemicals, Materials, and Energy. Radiant Insights has a strong base of analysts, consultants and domain experts, with global experience helping us deliver excellence in all research projects we undertake.

Logo: http://www.abnewswire.com/pressreleases/wp-content/uploads/2016/03/1459410143.png

“Radiant Insights”

Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: sales@radiantinsights.com
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States
Website: http://www.radiantinsights.com/research/market-snapshot-glucose-monitoring-devices-2006-to-2020-southeast-asia-taiwan-indonesia-malaysia-singapore-vietnam

Source: ABNewswire

ReleaseID: 57832

Growing health consciousness of people stands as one of the major driving factor for Functional Food and Nutraceuticals Market. Research claims that the market will grow at a CAGR of 8.5% by 2020.

The Report “Functional Food and Nutraceuticals Market – By Type (Foods, Beverages, Supplements); Benefits (Health and Wellness, Disease Prevention, Fitness, Beauty); Origin & Ingredient – Forecast (2015-2020)” published by IndustryARC, estimates that the market will reach $305.4 Billion by 2020.

Functional Foods and Nutraceuticals, though lacking a precise definition, refers to food which provides additional nutritional and health benefits apart from conventional food. The recent trend has seen an upsurge of such “Health Foods” which include dietary supplements containing vitamins, minerals, herbs and others. The increasing Health Awareness and easily available Nutrition Deficiency products have made a strong impact for Functional Food Market on Global Economy.

Inquiry before Buying @ http://www.industryarc.com/inquiry-before-buying.php?id=99

Market Drivers:

The Functional Foods Market is driven by the increasing Health conscious nature of people. The trend of being preventive rather than reactive to health issues has also spurred on the market and has increased the demand of products that provided additional nutrition and are healthy. The Functional Food has now expanded and is present in almost all the types of food consumed by humans including: cereals, nuts, vegetables, fruits, dairy products, confectionery items and also from snacks to non-alcoholic beverages. In today’s Nutraceutical Market it is possible to get a “Health Food” alternative in any of the above categories.

Market Segmentation:

The Functional Food Market is segmented into six main categories, it is divided based on: Type, Benefits, Origin, Ingredients, Consumer and Geography. The different types of Functional Food include: food, beverages and supplements. The market is driven by the benefits these Functional Foods provide, which are: Health and Wellness, Disease Prevention, Fitness and Beauty. All functional food is derived from two sources, either Plants or Animals. The Market is also classified based on the Ingredients used in the synthesis, they include; Anti-oxidants, Carotenoids, Fatty Acids, Flavonoids and Minerals among others. Nutraceutical Products are also classified based on its consumer; Adults, Children and Elderly. The last classification is based on Geography, the main regions are: Americas, Asia Pacific, Europe and Rest of the World.

Request a Sample Brochure @ http://www.industryarc.com/pdfdownload.php?id=99

Market Growth:

The Functional Food and Nutraceutical Market is estimated to grow at an Annual Average Growth Rate of about 8.5% in the forecast period 2015-2020 according the Market Report by IndustryARC.

• The Market Size is predicted to rise from $168 Billion in 2013 to $305.4 Billion in 2020.
• The highest growth in the market is being recorded in the energy drinks, healthy snacks and breakfast products sectors.

Key Players:

Different sectors of the Functional Food Market have different key players that dominate the Market.

• Red Bull GmbH is world leader in Energy Drinks having Market Share of more than 40%.
• Pepsi Co. and Kellogg Co. are world leaders in Healthy Snacks.
• Groupe Danone and Groupe Lactilas dominate the Healthy Dairy Products.
• Yakult Honsha Co. Ltd. is a leader in Probiotic Drinks sector.

Related Reports of Your Interest:

Nutritional Premixes Market:Type (Nucleotides, Nutraceuticals, Other) Application (Infant Nutrition, Dairy products, Bakery & Confectionary, Nutraceuticals Supplements, Other) Functionally (Bone Health, Beauty, Immunity, Other) Form (Powder, Liquid) – Forecast (2015-2020):
http://industryarc.com/Report/15005/nutritional-premixes-market.html

About IndustryARC:

IndustryARC is a research and consulting firm that publishes more than 500 reports annually in various industries, such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food & Beverages, Information Technology, Life sciences & Healthcare.

IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications of the Market. Our Custom Research Services are designed to provide insights on the constant flux in the global demand-supply gap of markets. Our strong analyst team enables us to meet the client research needs at a very quick speed with a variety of options for your business.

We look forward to support the client to be able to better address customer needs; stay ahead in the market; become the top competitor and get real-time recommendations on business strategies and deals. Contact us to find out how we can help you today.

Logo: http://www.abnewswire.com/pressreleases/wp-content/uploads/2016/03/1459318944.jpeg

“Functional Food Market generated a revenue of $168 Billion in 2013.”

Media Contact
Company Name: IndustryARC
Contact Person: Mr. Sanjay Matthews
Email: sales@industryarc.com
Phone: 1-614-588-8538 (Ext: 101)
Country: United States
Website: http://www.industryarc.com

Source: ABNewswire

ReleaseID: 57826